Immatics’ PRAME gift keeps on giving
The company dribbles out more data on IMA203, and the numbers head in the right direction.
The month ahead: May’s remaining events
ASCO is fast approaching, but in the meantime Olema will have an important readout.
Merck joins the TIGIT pivotal failure club
Keyvibe-010 fails, but not for the reason you might have expected.
MacroGenics gets that sinking feeling
Tamarack data reveal vobra-duo’s toxicity, and wipe out the past six months’ share price gains.
CytomX delivers a pancreatic surprise
But the group’s attempt to join Janux at the high altar of masking technology falls flat.
Calliditas puts a brave face on setanaxib failure
A phase 2 head and neck trial missed its primary endpoint, but the group is taking heart from survival data.
